INNOVANCE Anti-Xa assay

INNOVANCE Anti-Xa assay1

Learn how the INNOVANCE® Anti-Xa assay1 helps streamline lab operations with a ready-to-use assay for heparin and direct oral anticoagulant (DOAC) testing.

Why your lab should perform anti-Xa testing for anticoagulants

To monitor and manage bleeding risks, labs are asked to safeguard anticoagulant therapies such as heparin or direct oral anticoagulants (DOACs) by testing patients for a growing number of agents.

Direct oral anticoagulants such as rivaroxaban and apixaban are direct anti-Xa inhibitor drugs that have evolved over time because of their convenient dosing and short half-life. Though the medication usually does not require monitoring, DOAC testing is needed to properly manage individuals with bleeding conditions, emergency situations that require unplanned surgery, and relevant comorbidities (e.g., renal insufficiency).

Heparin is a traditional anticoagulant drug that exists in two forms—UFH and LMWH—both of which considerably accelerate the inactivation of coagulation factor Xa by antithrombin. Clinical data shows that monitoring heparin with an anti-Xa assay has several advantages over APTT testing:2-6

  • A smoother dose-response curve
  • More-stable heparin levels during therapy
  • Fewer blood samples required
  • Fewer dosage adjustments  

Brochure preview

The INNOVANCE Anti-Xa assay1 is available on multiple platforms and supports.
For details on available assay applications or ordering information, download a copy of the hemostasis reagent portfolio catalog.

Don’t miss these events!

1
2
3
4
5
6